Teva Denied On LAI Risperidone But Expected To Bounce Back ‘Quickly’

Israeli Firm ‘Reviewing Its Next Steps’ And Will ‘Work Closely’ With FDA

 
• By Dean Rudge
  
Hybrid
Teva and MedinCell are collaborating on a 505(b)(2) risperidone • Source: Shutterstock

More from Value Added Medicines

More from Products